How to access Trikafta from India — the named-patient import pathway, 2026

By Reserve Meds · Clinical & regulatory team · Last reviewed 2026-04-23

An Indian patient with cystic fibrosis (CF) whose CFTR genotype includes at least one F508del pathogenic variant, or another CFTR variant responsive to elexacaftor/tezacaftor/ivacaftor per FDA labelling, may receive a prescription for Trikafta (known as Kaftrio in some markets) from their treating CF pulmonologist. Trikafta is FDA-approved, developed by Vertex Pharmaceuticals, and is a triple-combination CFTR modulator that has meaningfully changed the disease trajectory for eligible CF patients. In India, Trikafta is not broadly registered for routine pharmacy dispensing, which is why your pulmonologist may be navigating a named-patient import pathway with you.

This guide explains the legal pathway, what your physician needs to provide, typical timelines, and where Reserve Meds fits in.

The clinical situation

Trikafta corrects and potentiates the defective CFTR chloride channel at the apical membrane of epithelial cells. It requires a responsive CFTR genotype — historically anchored on at least one F508del allele, with an expanded list of responsive variants based on in vitro and clinical data (check the current FDA label). Dosing is two morning tablets and one evening tablet daily, taken with fat-containing food for absorption. Eligibility anchors to confirmed CF diagnosis (sweat chloride, CFTR genotyping, and clinical phenotype), an FDA-responsive variant, age per labelling, and baseline hepatic and ophthalmological assessment (paediatric cataracts have been reported). Your pulmonologist will confirm genotype, baseline lung function (FEV1), and sweat chloride, and plan the hepatic monitoring cadence.

Is Trikafta legally importable into India?

Yes — via the Central Drugs Standard Control Organisation (CDSCO) Personal Use / Named-Patient import framework, which permits a treating physician to import a medicine not yet locally registered when (a) the medicine is approved by a recognised reference authority such as the US FDA, (b) no clinically equivalent alternative is routinely available, (c) the physician accepts clinical responsibility, and (d) chain of custody through a licensed importer is documented. CDSCO issues a personal-use licence keyed to the individual patient and a specified quantity consistent with the dosing plan; CF is a long-horizon chronic condition and applications routinely cover multi-month dispensation cycles.

How the pathway works, step by step

1. Consultation with your treating CF pulmonologist. Confirmed CF diagnosis, CFTR genotype, baseline FEV1, sweat chloride, and clinical rationale letter.
2. Genotype verification. CFTR genotyping report documenting an FDA-responsive variant.
3. CDSCO personal-use import application. Your physician or the importing licensed pharmacy files the dossier including rationale, patient reference, and dosing plan.
4. US-side sourcing. Reserve Meds coordinates with our US-licensed specialty wholesale partner to secure Trikafta from the manufacturer's authorised distribution chain under DSCSA.
5. Controlled shipment. Trikafta ships with standard temperature-controlled logistics and full chain-of-custody documentation to the importer of record.
6. Initiation and ongoing refill cadence. Your CF team initiates therapy with baseline liver-function and visual assessment, and monitors per FDA labelling.

What documentation your physician needs

• Clinical rationale letter confirming CF diagnosis, CFTR genotype (with FDA-responsive variant), baseline lung-function status, and Trikafta as the indicated therapy
• Verification of NMC / MCI registration
• CFTR genotyping report
• Sweat chloride test result
• Baseline liver-function panel and ophthalmological assessment (paediatric)
• Multi-month dosing plan with refill cadence

Reserve Meds provides a physician documentation kit bundling the CDSCO templates reviewers expect to see for CF named-patient files, designed around the reality that CF is a multi-year treatment horizon and the file supports ongoing refill cycles.

Costs and timing

Trikafta's US cash-pay reference cost sits in an indicative 2026 annual range of roughly USD 320,000–340,000. International logistics, CDSCO documentation handling, importer-of-record fees, and concierge coordination add incremental cost. Reserve Meds issues a transparent quote at the start of intake, and refill cycles carry lower recurring coordination overhead than the initial application. These figures are indicative, not guaranteed.

Indicative timing — not guaranteed — for first dispensation after cohort intake opens is approximately 14–28 days from the moment a complete CDSCO application is submitted.

Reserve Meds is in pre-launch. Fulfillment availability is limited to our first cohort, and all timelines published on this site are indicative. If your clinical situation is time-sensitive, flag that when you join the waitlist — we triage accordingly.

A culturally-aware note: the Indian CF registry has grown substantially over the last decade and the Indian CF community includes both south-Indian and north-Indian genotype clusters; F508del is present in a meaningful minority but not all Indian CF families will have a Trikafta-responsive variant. Your pulmonologist's genotype-based eligibility determination is the gating step.

Reserve Meds's role

• Sourcing. Through our US-licensed specialty wholesale partner under DSCSA chain-of-custody.
• Documentation. Regulatory package for your physician and CDSCO review, keyed to the CFTR-genotype rationale.
• Logistics. Shipment to the nominated hospital pharmacy with importer-of-record handling.
• Concierge case lead. A named point of contact supporting ongoing refill cycles over the multi-year treatment horizon.

What we do not do: we are not the prescriber, we do not practise medicine, and we are not the dispensing pharmacy. All clinical decisions remain with your treating pulmonologist. We operate on a waitlist basis during our pre-launch phase.

Frequently asked

My child's genotype is not F508del-homozygous — are they eligible? The FDA-responsive variant list includes many non-F508del CFTR variants on both in vitro and clinical-trial-derived grounds. Your pulmonologist will check your specific variants against the current label.

What about age cut-offs? FDA labelling has expanded progressively to younger age groups. Current labelling covers very young children with qualifying variants; your pulmonologist confirms.

Is the generic version the same? Generic and unlicensed copies exist in some markets; these are not what we source. We coordinate the licensed US-origin product through DSCSA-chain-of-custody channels.

Will insurance cover this? Cash-pay is the default for named-patient imports. Some Indian private insurers and NGO assistance programmes consider case-by-case reimbursement for CF; we supply documentation but do not process claims directly.

Next step — join the first-cohort waitlist

Reserve Meds is opening to a limited first cohort in 2026. Add your case to the waitlist and our concierge case lead will reach out when we enter intake for Trikafta coordination.

Add me to the Trikafta waitlist

> Examples and timings above are composite illustrations drawn from published sources and typical named-patient patterns. Your individual case is assessed by your physician and our clinical-regulatory team; Reserve Meds does not guarantee outcomes or timelines.

---

Reserve Meds is a US-based concierge coordinator for cross-border specialty medicine. We are in pre-launch; service availability is limited to our first cohort and published timelines are indicative, not guarantees. Cash-pay. Export-only (US → overseas). Composite case examples. Not medical advice.

Clinical & regulatory review: Reserve Meds clinical team and AI regulatory-counsel review pipeline. Last medically reviewed: 2026-04-23.